NTT Enhancing INDYCAR Fan Experience and Safety at Indianapolis Motor Speedway
In preparation for the rescheduled 104th Indianapolis 500 presented by Gainbridge, NTT Corporation (NTT) today announced enhancements to Indianapolis Motor Speedway (IMS) that will accelerate smart technologies to improve the INDYCAR fan experience and safety when the Greatest Spectacle in Racing returns Sunday, Aug. 23, 2020.
“We are excited that when fans arrive at IMS for the Indy 500 they will be greeted with an improved, world-class and one-of-a-kind trip to the Racing Capital of the World,” said Mark Miles, Penske Entertainment Corp. President & CEO. “The future of sports will be driven by the ability to use technology to enhance fan experience, safety and convenience. NTT is helping IMS and INDYCAR find new and exciting ways to blend tradition with innovation and ultimately preserve and further The Greatest Spectacle in Racing’s history of discovery and progress.”
NTT will leverage the company’s Accelerate Smart data platform to power a 100-foot wide Media Wall at the base of the landmark Pagoda building, which will provide fans with access to data-driven race insights in real-time. The debut of the highly visible Media Wall will capture fans’ attention with 3D experiences, visualization of 143 data points from every car and multiple live feeds throughout the track. NTT’s Accelerate Smart platform will also use machine learning to indicate where cars should be on the track and predict their next move, while AI will pinpoint the best on-track battles and highlight head-to-head matchups in real-time with pit predictions, top speeds and more.
“NTT’s Accelerate Smart platform is super-charging efforts to significantly enhance the fan-experience at IMS. At this year’s Indy 500, the platform’s statistics and information will power a transformed Pagoda Plaza experience, providing key and engaging competition insights never previously available to in-venue fans in real time,” said Indianapolis Motor Speedway President, J. Douglas Boles. “In addition, NTT will also boost our safety and security grid, contributing to the well-being of spectators and event participants at the world’s largest single-day sporting event.”
At IMS, NTT’s Accelerate Smart solution includes safety and security measures that will offer more effective event security operations and oversight. Data analytics and insights will provide crowd and vehicle congestion detection and alerts that predict rates based on trends at the gates and tunnels. The digital-enabled, enhanced safety and security will establish a model to promote a consistent experience at IMS, as well as all INDYCAR venue events.
“The future of sport means providing fans with digital-first content, better access to technology and leveraging venues, such as IMS, to engage fans through new channels,” said Akira Shimada, Senior Executive Vice President, NTT. “Our Accelerate Smart data platform allows us to digitally transform INDYCAR’S fan engagement to retain its standing as a leader in motorsports, while also creating a safer race day experience.”
Penske and IMS leadership have made connectivity a key theme of investment to allow fans access to as much data and information in real-time as possible. As part of the digital focus, NTT has also evolved the INDYCAR Mobile app powered by NTT DATA to provide fans a second screen to view live in-car camera video during races, track weather forecasts, create and follow fantasy teams, watch on-demand highlights and more.
NTT’s is committed to accelerating the future of smart racing and creating the next generation of INDYCAR fans who want to enjoy the sport through a more digital experience. This is in part why NTT, a global information technology and communications leader, has been the title sponsor of the NTT INDYCAR SERIES since 2019, as well as the Official Technology Partner of INDYCAR, the NTT INDYCAR SERIES, Indianapolis Motor Speedway, Indianapolis 500 and NASCAR’s the Brickyard 400.
NTT believes in resolving social issues through our business operations by applying technology for good. We help clients accelerate growth and innovate for current and new business models. Our services include digital business consulting, technology and managed services for cybersecurity, applications, workplace, cloud, data center and networks all supported by our deep industry expertise and innovation.
As a top 5 global technology and business solutions provider, our diverse teams operate in 88 countries and regions and deliver services to over 190 of them. We serve 85% of Fortune Global 100 companies and thousands of other clients and communities around the world.
For more information on NTT, visit www.global.ntt/.
Drew Wilson, NTT DATA Services
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom